{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:54:18Z","timestamp":1773687258126,"version":"3.50.1"},"reference-count":51,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Canakinumab, a humanized anti-IL-1\u03b2 monoclonal antibody, is known for its ability to suppress IL-1\u03b2-mediated inflammation. However, continuous monitoring of its safety remains essential. Thus, we comprehensively evaluated the safety signals of canakinumab by data mining from FAERS. Methods: We used a disproportionate analysis to quantify canakinumab-related adverse events (AEs) using four algorithms. Clinical prioritization of the detected signals was assessed with a semiquantitative score method. Serious and non-serious outcomes were compared by statistical methods. Additionally, a stratification analysis of serious infections was conducted at the system organ class (SOC) level. Results: A total of 28,496 canakinumab-related AEs were collected, and 71 suspicious signals detected. Among these, 19 preferred terms (PTs) were identified as unexpected signals, including deafness, appendicitis, brain oedema, cushingoid, cellulitis, and papilledema. Of the AEs, 16 were more likely reported as serious outcomes, such as pneumonia, abdominal pain, deafness, and infection. Based on clinical priority score, 44 PTs were classified as weak, 27 as moderate, and none as strong. Furthermore, 30 PTs demonstrated a high level of evidence, primarily derived from FDA prescribing information, randomized controlled trials, and systematic reviews. Stratification analysis of infections and infestations (serious outcomes) revealed a stronger association of severe infections with canakinumab in older or heavier individuals. All positive signals followed an early failure pattern, with the incidence of canakinumab-associated AEs decreasing over time. Conclusions: We found that most of the suspicious signals were associated with infections. More attention should be paid to serious infections, particularly in males, individuals aged \u226560 years, or those weighing &gt;100 kg, who demonstrated the highest risk of serious infections.<\/jats:p>","DOI":"10.3390\/ph18010114","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T10:44:23Z","timestamp":1737024263000},"page":"114","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.3390","volume":"18","author":[{"given":"Weidong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"},{"name":"Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhou","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyu","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengling","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shupeng","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/s10165-012-0769-8","article-title":"Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan","volume":"23","author":"Yokota","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/art.42721","article-title":"Discovery of a Novel Missense Variant in NLRP3 Causing Atypical Cryopyrin-Associated Periodic Syndromes With Hearing Loss as the Primary Presentation, Responsive to Anti-Interleukin-1 Therapy","volume":"76","author":"Cohen","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Walker, U.A., Tilson, H.H., Hawkins, P.N., Poll, T.V., Noviello, S., Levy, J., Vritzali, E., Hoffman, H.M., Kuemmerle-Deschner, J.B., and Investigators, C.D.S. (2021). Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: Results from the beta-Confident Registry. RMD Open, 7.","DOI":"10.1136\/rmdopen-2021-001663"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kuemmerle-Deschner, J.B., Ramos, E., Blank, N., Roesler, J., Felix, S.D., Jung, T., Stricker, K., Chakraborty, A., Tannenbaum, S., and Wright, A.M. (2011). Canakinumab (ACZ885, a fully human IgG1 anti-IL-1\u03b2 mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res. Ther., 13.","DOI":"10.1186\/ar3266"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/annrheumdis-2016-209686","article-title":"Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS)","volume":"76","author":"Ozen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/1744666X.2023.2299230","article-title":"The clinical role of anakinra in the armamentarium against familial Mediterranean fever","volume":"20","author":"Parlar","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kuemmerle-Deschner, J.B., Kallinich, T., Henes, J., Kortus-G\u00f6tze, B., Oommen, P.T., Rech, J., Krickau, T., Weller-Heinemann, F., Horneff, G., and Janda, A. (2024). Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: Results from the interim analysis of the RELIANCE registry. RMD Open, 10.","DOI":"10.1136\/rmdopen-2023-003890"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gram, H. (2020). The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer. Pharmacol. Res., 154.","DOI":"10.1016\/j.phrs.2019.01.023"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1172\/JCI2629","article-title":"The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis","volume":"102","author":"Fishman","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3899\/jrheum.090316","article-title":"Functional association of interleukin 18 gene-607 (C\/A) promoter polymorphisms with disease course in Chinese patients with adult-onset Still\u2019s disease","volume":"36","author":"Chen","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yashiro, M., Furukawa, H., Asano, T., Sato, S., Kobayashi, H., Watanabe, H., Suzuki, E., Nakamura, T., Koga, T., and Shimizu, T. (2018). Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still\u2019s disease. Medicine, 97.","DOI":"10.1097\/MD.0000000000013394"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/BOR.0000000000000143","article-title":"Interleukin-1 as a therapeutic target in gout","volume":"27","author":"Dumusc","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/jcph.162","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis","volume":"53","author":"Chakraborty","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"mAbs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s10067-015-2889-y","article-title":"Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: A case-based review","volume":"34","author":"Aguiar","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.trsl.2019.08.003","article-title":"Atherothrombosis and the NLRP3 inflammasome\u2014Endogenous mechanisms of inhibition","volume":"215","author":"Satish","year":"2020","journal-title":"Transl. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ehjcvp\/pvad074","article-title":"Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease","volume":"10","author":"Zheng","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhou, J., Lu, H., and Pan, J. (2024). Association of Launch Price and Clinical Value with Reimbursement Decisions for Anticancer Drugs in China. Int. J. Health Policy Manag., 13.","DOI":"10.34172\/ijhpm.2024.8150"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pretre, V., Papadopoulos, D., Regard, J., Pelletier, M., and Woo, J. (2022). Interleukin-1 (IL-1) and the inflammasome in cancer. Cytokine, 153.","DOI":"10.1016\/j.cyto.2022.155850"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Paz-Ares, L., Goto, Y., Wan-Teck Lim, D., Halmos, B., Chul Cho, B., Cobo, M., Luis Gonz\u00e1lez Larriba, J., Zhou, C., Demedts, I., and Atmaca, A. (2024). Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. Lung Cancer, 189.","DOI":"10.1016\/j.lungcan.2023.107451"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.23.00910","article-title":"Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial","volume":"42","author":"Garon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.23.00980","article-title":"Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial","volume":"42","author":"Tan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/14397595.2018.1559488","article-title":"Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients","volume":"30","author":"Gulez","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/art.42808","article-title":"Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey","volume":"76","author":"Miyamoto","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.jaci.2019.12.909","article-title":"Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome","volume":"145","author":"Krause","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1021\/acs.jcim.3c01726","article-title":"MRNDR: Multihead Attention-Based Recommendation Network for Drug Repurposing","volume":"64","author":"Feng","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., and Zhang, Q. (2022). Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.996179"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shu, Y., Chen, J., Ding, Y., and Zhang, Q. (2023). Adverse events with risankizumab in the real world: Postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1169735"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of Interleukin-1\u03b2 by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Qiu, L., Ma, L., Xie, Y., Jin, J., Pan, Y., Li, S., Fan, Z., and Yu, H. (2024). Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience. Pediatr. Rheumatol. Online J., 22.","DOI":"10.1186\/s12969-024-00974-4"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Al-Mayouf, S.M., Al Mutairi, M., Bouayed, K., Habjoka, S., Hadef, D., Lotfy, H.M., Scott, C., Sharif, E.M., and Tahoun, N. (2021). Epidemiology and demographics of juvenile idiopathic arthritis in Africa and Middle East. Pediatr. Rheumatol. Online J., 19.","DOI":"10.1186\/s12969-021-00650-x"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2188\/jea.7.221","article-title":"Estimated prevalence and incidence of adult Still\u2019s disease: Findings by a nationwide epidemiological survey in Japan","volume":"7","author":"Wakai","year":"1997","journal-title":"J. Epidemiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Soluble immune effector molecules [II]: Agents targeting interleukins, immunoglobulins and complement factors)","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Rossi-Semerano, L., Fautrel, B., Wendling, D., Hachulla, E., Galeotti, C., Semerano, L., Touitou, I., and Kon\u00e9-Paut, I. (2015). Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: A nationwide survey. Orphanet J. Rare Dis., 10.","DOI":"10.1186\/s13023-015-0228-7"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes","volume":"70","author":"Hachulla","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/rheumatology\/kead514","article-title":"Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: A systematic review and meta-analysis","volume":"63","author":"Kilic","year":"2024","journal-title":"Rheumatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10067-020-05267-1","article-title":"A case of cryopyrin-associated periodic fever syndrome during canakinumab administration complicated by inflammatory bowel disease","volume":"40","author":"Yamasaki","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.55563\/clinexprheumatol\/fsq5vq","article-title":"The treatment of adult-onset Still\u2019s disease with anakinra, a recombinant human IL-1 receptor antagonist: A systematic review of literature","volume":"39","author":"Giacomelli","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes","volume":"378","author":"Gattorno","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/art.42695","article-title":"Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Results From a Phase III Trial","volume":"76","author":"Gattorno","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bent, R., Moll, L., Grabbe, S., and Bros, M. (2018). Interleukin-1 Beta\u2014A Friend or Foe in Malignancies?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082155"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Chandrakumaran, A., Malik, M., Stevens, M.P., and Abbate, A. (2018). A case report of locally invasive Aspergillus fumigatus infection in a patient on canakinumab. Eur. Heart J. Case Rep., 2.","DOI":"10.1093\/ehjcr\/yty098"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/jcpt.13701","article-title":"Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system","volume":"47","author":"Jiang","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Guo, M., Shu, Y., Chen, G., Li, J., and Li, F. (2022). A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-23726-4"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zhai, Y., Ye, X., Hu, F., Xu, J., Guo, X., Zhuang, Y., and He, J. (2019). Endocrine toxicity of immune checkpoint inhibitors: A real-world study leveraging US Food and Drug Administration adverse events reporting system. J. Immunother. Cancer, 7.","DOI":"10.1186\/s40425-019-0754-2"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40264-023-01334-z","article-title":"Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment","volume":"46","author":"Shu","year":"2023","journal-title":"Drug Saf."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Wang, X., Seyler, B.C., Chen, T., Jian, W., Fu, H., Di, B., Yip, W., and Pan, J. (2024). Disparity in healthcare seeking behaviors between impoverished and non-impoverished populations with implications for healthcare resource optimization. Humanit. Soc. Sci. Commun., 11.","DOI":"10.1057\/s41599-024-03712-z"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/1\/114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:30:06Z","timestamp":1759919406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/1\/114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ph18010114"],"URL":"https:\/\/doi.org\/10.3390\/ph18010114","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]}}}